ReviewClinics in liver disease2015
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Review in Clinics in liver disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis.Croatian medical journal · 2022Pooled it
- Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review.Digestive diseases and sciences · 2016Pooled it
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.Journal of hepatology · 2016Trial
- Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management.Diseases (Basel, Switzerland) · 2026Review
- [Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms].Problemy endokrinologii · 2025Review
- Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.Frontiers in oncology · 2025Review
- Effect of metformin on cell proliferation and apoptosis in steatosis HepG2 cell model.Northern clinics of Istanbul · 2025Article
- Microfluidic 3D hepatic cultures integrated with a droplet-based bioanalysis unit.Biosensors & bioelectronics · 2024Article
- Clinical Characteristics of Non-B and Non-C Biopsy-Proven Primary Liver Cancers in an HBV- Endemic Area: A Retrospective Study.Journal of hepatocellular carcinoma · 2024Article
- Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise.Metabolites · 2023Review
- Review
- Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes.Human molecular genetics · 2023Article
- Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.Biomedicines · 2023Review
- Integration analysis of miRNA-mRNA expression exploring their potential roles in intrahepatic cholangiocarcinoma.Scientific reports · 2023Article
- Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.Clinical and molecular hepatology · 2023Article
- How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography-A Review of the Literature and Proposed Multistep Approach.Diagnostics (Basel, Switzerland) · 2023Review
- Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.Gut and liver · 2023Review
- Construction of molecular typing in LIHC microenvironment based on lipid metabolism-related genes.American journal of cancer research · 2023Article
- Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.Frontiers in endocrinology · 2023Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC). NAFLD is the commonest cause of chronic liver disease. HCC can develop in NAFLD patients even without cirrhosis, suggesting an association between the metabolic process and HCC and raising a concern that many cancers could be missed given high NAFLD prevalence and screening limitations. The increasing prevalence of these conditions and lack of effective treatments necessitate a better understanding of their connection. This article defines the known interrelationships and common pathways between NAFLD, diabetes, obesity and HCC and possible chemoprevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.